ENSC vs. AVTX, KPRX, GHSI, VAXX, CMMB, LUMO, MNPR, IMNN, ERNA, and VCNX
Should you be buying Ensysce Biosciences stock or one of its competitors? The main competitors of Ensysce Biosciences include Avalo Therapeutics (AVTX), Kiora Pharmaceuticals (KPRX), Guardion Health Sciences (GHSI), Vaxxinity (VAXX), Chemomab Therapeutics (CMMB), Lumos Pharma (LUMO), Monopar Therapeutics (MNPR), Imunon (IMNN), Eterna Therapeutics (ERNA), and Vaccinex (VCNX). These companies are all part of the "pharmaceutical preparations" industry.
Avalo Therapeutics (NASDAQ:AVTX) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk, community ranking and media sentiment.
87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are owned by institutional investors. 0.3% of Avalo Therapeutics shares are owned by company insiders. Comparatively, 52.7% of Ensysce Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Ensysce Biosciences has a consensus price target of $7.00, indicating a potential upside of 1,535.90%. Given Avalo Therapeutics' higher possible upside, analysts plainly believe Ensysce Biosciences is more favorable than Avalo Therapeutics.
Ensysce Biosciences has a net margin of -660.96% compared to Ensysce Biosciences' net margin of -1,639.50%. Avalo Therapeutics' return on equity of -598.21% beat Ensysce Biosciences' return on equity.
Avalo Therapeutics has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500. Comparatively, Ensysce Biosciences has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500.
In the previous week, Avalo Therapeutics had 1 more articles in the media than Ensysce Biosciences. MarketBeat recorded 4 mentions for Avalo Therapeutics and 3 mentions for Ensysce Biosciences. Ensysce Biosciences' average media sentiment score of 1.14 beat Avalo Therapeutics' score of 0.72 indicating that Avalo Therapeutics is being referred to more favorably in the media.
Ensysce Biosciences has higher revenue and earnings than Avalo Therapeutics.
Avalo Therapeutics received 2 more outperform votes than Ensysce Biosciences when rated by MarketBeat users. However, 60.00% of users gave Ensysce Biosciences an outperform vote while only 31.25% of users gave Avalo Therapeutics an outperform vote.
Summary
Avalo Therapeutics and Ensysce Biosciences tied by winning 7 of the 14 factors compared between the two stocks.
Get Ensysce Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENSC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ensysce Biosciences Competitors List
Related Companies and Tools
